| Document |
Document Title |
|
WO/2022/265878A9 |
A composition for treating an individual while reducing acute effects, including effective amounts of a psychedelic drug and a duration shortening agent. A method of treating an individual with a psychedelic drug and reducing or eliminat...
|
|
WO/2023/138696A1 |
The present invention relates to a drug and method for nucleoside (acid) drug therapy of limiting chronic hepatitis B, in particular to the use of an HBV virus entry inhibitor and an optional immunomodulator in the preparation of a drug ...
|
|
WO/2023/140350A1 |
The present invention provides a pharmaceutical composition for suppressing organ fibrosis, characterized by having an angiotensin II receptor antagonist as an active ingredient, and being administered at a dosage of 0.2 times or less th...
|
|
WO/2023/139506A1 |
This invention provides method of treating hypertension in a hypertensive subject, the method comprising administering to the subject a CYP 11β2 beta hydroxylase inhibitor once or twiceper day in an amount sufficient to inhibit 50% or m...
|
|
WO/2023/140329A1 |
A medicine for treating or preventing cancer, the medicine comprising a first active ingredient used together with a second active ingredient, the first active ingredient being a compound expressed by formula (1) or a salt thereof or a s...
|
|
WO/2023/140385A1 |
A pharmaceutical composition for treating or preventing at least one disease selected from the group consisting of inflammatory bowel disease and intestinal tumor, said pharmaceutical composition comprising an inhibitor for the binding o...
|
|
WO/2023/141087A1 |
The present invention relates to combination therapy with (a) a mutant IDH inhibitor, or a pharmaceutically acceptable salt thereof, (b) a deoxyadenosine analog, or a pharmaceutically acceptable salt thereof, (c) a platinum agent, and (d...
|
|
WO/2023/137941A1 |
A nucleic acid aptamer and a use thereof. The nucleic acid aptamer is a nucleic acid aptamer that can specifically recognize bladder tumor cells and can internalize into the bladder tumor cells. The nucleic acid aptamer has good specific...
|
|
WO/2023/137659A1 |
A series of polymers having the properties of acid-sensitive degradation and temperature sensitivity and a drug loading composition thereof. A polymer has a structure represented by formula (1) and has the properties of degradation and t...
|
|
WO/2023/139381A1 |
An inhalable formulation comprising at least one amino acid and at least one beta-2-agonist is disclosed. The inhalable formulation may be administered by pressurized metered dose inhaler.
|
|
WO/2023/140309A1 |
[Problem] To elucidate the mechanism of an anti-tumor effect of a ketogenic diet therapy to discover a novel cancer treatment method. [Solution] Provided is a composition for treating cancer, the composition comprising a ketogenic diet t...
|
|
WO/2023/138593A1 |
Provided in the present invention are an antibacterial stent having a micro-nano double-layer structure, and a preparation method therefor and the use thereof, which belong to the technical field of oral medical products. The method for ...
|
|
WO/2023/138011A1 |
The present invention provides a translation inhibitor not occupying a ribosome resource. The translation inhibitor not occupying a ribosome resource shows a good antitumor effect, has high safety, and can be used for preparing an antitu...
|
|
WO/2023/139221A1 |
The present invention relates to an intravaginal ring (1) a core (2) comprising a first ethylene-vinyl acetate copolymer (3) having a vinyl acetate content from 28 to 40 wt%, and at least 10 wt% of an estrogenic steroid (4) based on the ...
|
|
WO/2023/140717A1 |
The present invention relates to a chitosan-heparin nanomotor and a method for producing same. A STING antagonist-filled urease-based chitosan-heparin nanomotor delivers the STING antagonist directly to bladder mucosal cells in the bladd...
|
|
WO/2023/139233A1 |
The present invention relates to A pharmaceutical combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, prodrug thereof or a metabolite thereof with a JAK inhibitor or a pharmaceutically acceptable salt ...
|
|
WO/2023/134202A1 |
The use of capsular polysaccharide A from Bacteroides fragilis and immune checkpoint inhibitors in preparation of drugs for treating digestive system tumors. The capsular polysaccharide from Bacteroides fragilis is capsular polysaccharid...
|
|
WO/2023/135506A1 |
Provided is (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,
4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Etrasimod, Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof for use in a method of t...
|
|
WO/2023/134195A1 |
Disclosed is the use of Bacteroides fragilis combined with an immune checkpoint inhibitor in the treatment of skin tumors, in particular to the combination of Bacteroides fragilis ZY-312 with the deposit number of CGMCC No. 10685 and a P...
|
|
WO/2023/134205A1 |
Provided are a drug containing Bacteroides fragilis, in particular to Bacteroides fragilis ZY-312 having a deposit number of CGMCC No.10685, and a PD-1 antibody and/or a PD-L1 antibody, and a use of the drug in correcting an immune cell ...
|
|
WO/2023/134201A1 |
Disclosed in the present invention is the use of a combination of Bacteroides fragilis and an immune checkpoint inhibitor in the treatment of digestive system tumors, in particular to the combined use of Bacteroides fragilis ZY-312 with ...
|
|
WO/2023/135827A1 |
This invention addresses the problem of providing a novel agent for preventing and/or curing neurodegenerative diseases. The invention relates to an agent for preventing and/or curing neurodegenerative diseases, the agent comprising a ...
|
|
WO/2023/135950A1 |
[Problem] To examine the influence proteoglycans exhibit on immune responses induced by a variety of immunogenic factors that act on dendritic cells, macrophages, and other such immune cells, and provide an agent or composition that is u...
|
|
WO/2023/135978A1 |
Provided is a drug for treating aftereffects of a novel coronavirus infection. The drug for treating aftereffects of the novel coronavirus infection contains an acetylcholine receptor agonist as an active ingredient.
|
|
WO/2023/134203A1 |
Disclosed is an application of bacteroides fragilis and/or a zwitterionic capsular polysaccharide thereof in the preparation of a drug for treating a respiratory system tumor. Bacteroides fragilis, and particularly bacteroides fragilis Z...
|
|
WO/2023/137178A1 |
Provided is a health supplement product that can be administered to subjects with pre-diabetes and type 2 diabetes, the product comprising a fixed dose combination of vitamin D3, niacinamide (which is a form of vitamin B3), and lipoic ac...
|
|
WO/2023/134688A1 |
A salt of a ROCK inhibitor, a crystal form of the salt, a composition, and a pharmaceutical use. The salt and the crystal form of the salt are an acid addition salt of a compound I and any acid in the following and a crystal form thereof...
|
|
WO/2023/135505A1 |
The present disclosure relates to methods for treating Sjögren's Syndrome or mixed connective tissue disease using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein is a compound of Formula (...
|
|
WO/2023/135274A1 |
The present invention is directed to fermented cereal compositions for treatment of a fatty liver disease or a fibrotic liver disease.
|
|
WO/2023/134730A1 |
The present invention provides a pyrrolidine compound represented by formula (I) and a pharmaceutically acceptable salt thereof, and a use thereof as a coronavirus 3CL protease inhibitor in the prevention or treatment of related diseases...
|
|
WO/2023/137227A1 |
A multivesicular lipid nanoparticle composition includes a plurality of multivesicular lipids. Each multivesicular lipid nanoparticle includes a carrier phospholipid micelle including a carrier phospholipid layer and having an average di...
|
|
WO/2023/135949A1 |
[Problem] To examine the influence proteoglycans exhibit on immune responses induced by a variety of immunogenic factors that act on dendritic cells, macrophages, and other such immune cells, and provide an agent or composition that is u...
|
|
WO/2023/134194A1 |
An application of bacteroides fragilis capsular polysaccharide A in combination with a PD-1 inhibitor in the preparation of a pharmaceutical for treating skin tumors; in particular, capsular polysaccharide A of bacteroides fragilis ZY-31...
|
|
WO/2023/134210A1 |
The present invention relates to a new application of Bacteroides fragilis capsular polysaccharide A and an immune checkpoint inhibitor, and mainly relates to an application of the Bacteroides fragilis capsular polysaccharide A and the i...
|
|
WO/2023/132333A1 |
A pharmaceutical composition for treating cancer that contains a substance binding to laeverin; a method for identifying cancer recurrence and/or metastasis; a method for identifying a substance that impairs cancer cells expressing laeve...
|
|
WO/2023/133086A1 |
Disclosed herein are methods and compositions for treating cancer using an incomplete autophagy inducer, such as metixene (aka. "methixene"), to trigger caspase-mediated apoptosis in cancer cells. The described methods and compositions c...
|
|
WO/2023/133319A1 |
Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist in combination with immunosuppressants (e.g., comprised in synthetic nanocarriers), wherein the immunosuppressant is at a reduced effe...
|
|
WO/2023/133321A1 |
The present disclosure provides novel methods for treating, preventing, ameliorating, inhibiting and/or delaying the onset of tauopathies. The methods comprise administering to the subject an effective amount of a small molecule peptidom...
|
|
WO/2023/131579A1 |
The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts in the treatment of congenital muscular dystrophies, especially Duchenne muscular dystrophy or Becker mu...
|
|
WO/2023/130758A1 |
The present invention provides a sustained-release drug delivery system for oral administration, and a preparation method therefor. According to the present invention, a drug for treating oral diseases is loaded on a porous material, and...
|
|
WO/2023/133460A1 |
Disclosed herein are methods of treating an allergic rhinitis, a nasal polyp, and/or a sinusitis in a subject, comprising intranasally administering to the subject a corticosteroid, an ester thereof, or a salt thereof by a nasal spray de...
|
|
WO/2023/131576A1 |
The present invention pertains to the treatment of proliferative diseases, such as cancer. In particular, the invention describes a novel combination therapy strategy, comprising a Receptor-interacting serine/threonine-protein kinase 1 (...
|
|
WO/2023/131720A1 |
The invention relates to a compound of formula (I), for use in treating GM2 gangliosidosis, specifically Sandhoff disease or Tay-Sachs disease. Specifically, the invention relates to a compound of formula (I) for use in increasing surviv...
|
|
WO/2022/109178A9 |
Provided herein are anti-MARCO antibodies. Provided are also methods of generating and using anti-MARCO antibodies.
|
|
WO/2023/131063A1 |
A bispecific antigen-binding molecule specifically binding to MSLN and NKG2D ligand (NKG2DL), a bispecific chimeric antigen receptor containing the bispecific antigen-binding molecule, a modified immune cell expressing the bispecific chi...
|
|
WO/2023/130188A1 |
The present invention provides methods of treating cancer by modulating regulators of IL-33. Also provided are methods of preventing tumor metastasis and/or cancer progression by treatment with agents that modulate FOX1A. Also provided a...
|
|
WO/2023/131323A1 |
The invention provides personal neoantigen vaccines, and uses thereof. The invention also provides markers MX1 and PPP1R15A, and uses thereof. The invention also provides sets of biomarkers, and uses thereof.
|
|
WO/2023/133576A1 |
Hydration of a larynx and/or vicinity with a composition comprising a salt formulation (e.g., CaCl2, MgCl2, KCl and/or NaCl) can achieve prophylactic and/or therapeutic effects (e.g., cough suppression, improving voice quality, increasin...
|
|
WO/2023/132842A1 |
A method for treating an early-stage microbial infection comprising determining whether a subject is exposed to a coronavirus, such as SARS-CoV-2, or suspected of being exposed to a coronavirus, or exposed to another infected with or sus...
|
|
WO/2023/127600A1 |
The present invention addresses the problem of providing a novel drug for treating SITH-1-associated diseases. The problem is solved by a drug for treating SITH-1-associated diseases, the drug containing a cholinergic agonist as an activ...
|
